SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bliss GVS Pharma - Quaterly Results

24 Jan 2023 Evaluate
The sales slipped to Rs. 1687.92 millions for the December 2022 quarter as against Rs. 1905.97 millions during the year-ago period.The Company has registered profit of Rs. 292.80  millions for the quarter ended December 2022, a growth of 7.75%  over Rs. 271.74 millions millions achieved in the corresponding quarter of last year.Operating profit for the quarter ended December 2022 rose to 448.84 millions as compared to 381.34 millions of corresponding quarter ended December 2021.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 1687.92 1905.97 -11.44 4549.21 4980.55 -8.66 6363.57 4655.13 36.70
Other Income 114.23 63.10 81.03 442.88 201.92 119.33 326.28 176.83 84.52
PBIDT 448.84 381.34 17.70 1235.32 1107.11 11.58 1418.26 1091.43 29.95
Interest 12.03 9.52 26.37 50.84 27.87 82.42 43.24 41.94 3.10
PBDT 436.81 399.27 9.40 1184.48 1106.69 7.03 1402.47 1049.49 33.63
Depreciation 37.90 35.14 7.85 111.99 104.41 7.26 138.47 137.62 0.62
PBT 398.91 364.13 9.55 1072.49 1002.28 7.01 1264.00 911.87 38.62
TAX 106.11 92.39 14.85 278.78 266.69 4.53 337.36 236.86 42.43
Deferred Tax -12.71 -7.91 60.68 -17.41 -6.59 164.19 7.68 11.69 -34.30
PAT 292.80 271.74 7.75 793.71 735.59 7.90 926.64 675.01 37.28
Equity 104.15 103.68 0.45 104.15 103.68 0.45 103.68 103.15 0.51
PBIDTM(%) 26.59 20.01 32.91 27.15 22.23 22.16 22.29 23.45 -4.94

Bliss GVS Pharma Share Price

253.40 -4.95 (-1.92%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×